Industry Overview

India prostate cancer diagnosis & treatment market was valued at $1,242.0 million in 2025 and is projected to reach $2,990.4 million by 2035, growing at a CAGR of 9.2% during the forecast period (2026-2035). The market is growing due to the increasing incidence of prostate cancer, particularly among the aging male population. Rising awareness regarding early screening through prostate-specific antigen testing and digital rectal examination is contributing to higher diagnosis rates. Continuous advancements in diagnostic technologies and imaging accuracy are improving early detection and risk stratification. Expanding availability of advanced therapeutic options, including immunotherapy and targeted therapy, is enhancing treatment outcomes and patient survival. In addition, supportive reimbursement frameworks and strengthening oncology infrastructure across emerging and developed economies are reinforcing sustained market expansion.

Market Dynamics

Rising Disease Burden and Expanding Diagnostic Adoption

The rising incidence of prostate cancer, particularly among men above 60 years of age, remains a primary growth driver for the prostate cancer diagnosis and treatment market. Demographic shifts toward an aging population are directly increasing the patient pool requiring routine screening, confirmatory diagnostics, and long-term therapeutic management. Clinical guidelines in several countries recommend regular prostate-specific antigen testing and digital rectal examination for high-risk groups, supporting consistent diagnostic volumes. Improvements in laboratory accuracy, biomarker validation, and imaging integration are strengthening early-stage detection rates. Earlier diagnosis is leading to higher treatment initiation, thereby sustaining demand across hormonal therapy, radiation therapy, chemotherapy, immunotherapy, and targeted therapy segments.

Advancements in Therapeutic Innovation and Clinical Infrastructure

Continuous advancement in treatment innovation and precision oncology represents another major driver for market expansion. Pharmaceutical companies are expanding pipelines focused on next-generation hormonal agents, radioligand therapies, and immune-based approaches designed to improve survival outcomes in advanced and metastatic cases. Regulatory approvals for novel targeted therapies are broadening the available treatment landscape and encouraging earlier adoption in clinical practice. Expansion of specialized oncology centers and improved access to reimbursement in key healthcare systems are increasing therapy uptake. Growing clinical research activity and participation in oncology trials are accelerating the introduction of differentiated therapeutic options, reinforcing sustained market growth.

Market Segmentation

• Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
• Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.

Hormonal Therapy Anchoring Treatment Expansion

Hormonal therapy remains the largest therapeutic sub-segment in India’s prostate cancer treatment landscape, largely because it is widely used for both localized and advanced disease stages. Rising diagnosis among aging male populations and improved access to oncology services in metropolitan hospitals have strengthened demand for androgen-deprivation therapies. The country’s prostate cancer therapeutics market generated about USD 469 million in 2024 and continues expanding as treatment accessibility improves. Leading pharmaceutical companies such as Astellas Pharma, Bayer AG, and Merck & Co. supply androgen-receptor inhibitors and hormone-based treatment regimens widely used in clinical practice. Increased physician preference for oral hormonal agents and combination therapy protocols is further supporting uptake. Recent clinical adoption of next-generation androgen receptor inhibitors and long-acting injectable therapies has enhanced treatment adherence and patient outcomes.

Advanced Radiation Therapy Gaining Rapid Traction

Radiation therapy represents one of the fastest advancing treatment segments in the Indian prostate cancer market as hospitals increasingly invest in precision oncology infrastructure. Technological progress in image-guided and intra-operative radiation methods has enabled clinicians to deliver higher accuracy treatment with fewer side effects. Several cancer centers across India are expanding radiotherapy facilities to manage rising cancer burden and improve survival outcomes. The radiation therapy segment alone is projected to grow strongly through 2033 due to increasing adoption of advanced treatment platforms. Medical technology companies such as Elekta, Siemens Healthineers, and Varian Medical Systems supply radiotherapy equipment used in major oncology centers. A notable trend includes the introduction of intra-operative electron radiation therapy in specialized hospitals, reflecting the country’s gradual transition toward precision-guided cancer treatment.

Market Players Outlook

The major companies operating in the India prostate cancer diagnostic and therapeutic market include Roche, Johnson & Johnson, Pfizer, Novartis, AstraZeneca among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In February 2026, Bayer received approval in India to expand the indication of Nubeqa (darolutamide) for use in combination with androgen-deprivation therapy in men with metastatic hormone-sensitive prostate cancer, offering a non-chemotherapy treatment option. This is significant as a large proportion of Indian patients with advanced disease are unable to tolerate chemotherapy due to age or comorbid conditions. The approval is supported by data from the global Phase III ARANOTE trial, in which India contributed 14% of total enrolment, including participation from All India Institute of Medical Sciences.

• In 2024, Apollo Hospitals introduced South India’s first water vapour thermotherapy (REZUM) for the treatment of enlarged prostate (BPH). The minimally invasive procedure uses controlled steam injections to reduce excess prostate tissue without major surgery and is completed within 10–15 minutes under mild sedation.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the India prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.